相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Cristina Jimenez et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration
H. Robert Bergen et al.
CLINICAL CHEMISTRY (2016)
Utility of CD54, CD229, and CD319 for the Identification of Plasma Cells in Patients with Clonal Plasma Cell Diseases
Fanny Pojero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Measuring Disease Levels in Myeloma Using Flow Cytometry in Combination with Other Laboratory Techniques: Lessons from the Past 20 Years at the Leeds Haematological Malignancy Diagnostic Service
Andy C. Rawstron et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Consensus Guidelines for Myeloma Minimal Residual Disease Sample Staining and Data Acquisition
Maryalice Stetler-Stevenson et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma
Juan Flores-Montero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Ken Herrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
M. B. Meads et al.
ONCOGENE (2016)
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Carolina Terragna et al.
ONCOTARGET (2016)
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen
Ruth M. de Tute et al.
HAEMATOLOGICA (2016)
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Bruno Paiva et al.
BLOOD (2016)
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Bruno Paiva et al.
BLOOD (2016)
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients
Karen Shires et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study
Iole Cordone et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
Yinlei Bai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
C-11-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
Constantin Lapa et al.
THERANOSTICS (2016)
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Joaquin Martinez-Lopez et al.
BLOOD (2015)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
Andy C. Rawstron et al.
BLOOD (2015)
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
Elena Zamagni et al.
CLINICAL CANCER RESEARCH (2015)
Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Bruno Paiva et al.
CLINICAL CANCER RESEARCH (2015)
Old and New Immunophenotypic Markers in Multiple Myeloma for Discrimination of Responding and Relapsing Patients: The Importance of Normal Residual Plasma Cell Analysis
Fanny Pojero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma
Kathrin Philipp-Abbrederis et al.
EMBO MOLECULAR MEDICINE (2015)
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma A Comparison with Real-Time PCR
Daniela Drandi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
N. Puig et al.
LEUKEMIA (2015)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside
Sham Mailankody et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia
Jizhong Liu et al.
ONCOTARGET (2015)
Overcoming nutrient limitations for cell-based production of influenza vaccine
Sara Yousef et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Deep Response in Multiple Myeloma: A Critical Review
Mariateresa Fulciniti et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde et al.
JAMA ONCOLOGY (2015)
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Bruno Paiva et al.
HAEMATOLOGICA (2015)
Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma
Sang-Yong Shin et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2015)
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
T. Paino et al.
LEUKEMIA (2015)
Low-energy laser irradiation promotes cellular damage in glucocorticoid-resistant multiple myeloma cells
Alessandro Allegra et al.
LEUKEMIA & LYMPHOMA (2015)
The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma
Kirsty Wienand et al.
PLOS ONE (2015)
α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
Katharina Teiluf et al.
ONCOTARGET (2015)
Utility of Nine-Color, 11-Parameter Flow Cytometry for Detection of Plasma Cell Neoplasms A Comparison With Bone Marrow Morphologic Findings and Concurrent M-Protein Studies in Serum and Urine
Amir Behdad et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
Ola Landgren et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Robust isolation of malignant plasma cells in multiple myeloma
Ildiko Frigyesi et al.
BLOOD (2014)
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Wilson I. Gonsalves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets
Alessandro Allegra et al.
CANCER INVESTIGATION (2014)
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
Damian J. Green et al.
CANCER RESEARCH (2014)
State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings
Charles Mesguich et al.
EUROPEAN JOURNAL OF RADIOLOGY (2014)
Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets
Gina Y. Kim et al.
GENES CHROMOSOMES & CANCER (2014)
In Multiple Myeloma, 14q32 Translocations Are Nonrandom Chromosomal Fusions Driving High Expression Levels of the Respective Partner Genes
Erming Tian et al.
GENES CHROMOSOMES & CANCER (2014)
Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Maxime Janin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
Murielle Roussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR
Lawrence J. Jennings et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LC-MS/MS
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Association of response endpoints with survival outcomes in multiple myeloma
S. Lonial et al.
LEUKEMIA (2014)
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L. Melchor et al.
LEUKEMIA (2014)
New orally active proteasome inhibitors in multiple myeloma
Alessandro Allegra et al.
LEUKEMIA RESEARCH (2014)
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
Prashant R. Tembhare et al.
LEUKEMIA RESEARCH (2014)
Comparison of Droplet Digital PCR and Seminested Real-Time PCR for Quantification of Cell-Associated HIV-1 RNA
Maja Kiselinova et al.
PLOS ONE (2014)
Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
Ju Bai et al.
PROTEOME SCIENCE (2014)
Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients
Elizabeth R. Remily-Wood et al.
PROTEOMICS CLINICAL APPLICATIONS (2014)
Response evaluation and monitoring of multiple myeloma
Carlos Fernandez de Larrea et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
R. Silvennoinen et al.
BLOOD CANCER JOURNAL (2014)
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
B. A. Walker et al.
BLOOD CANCER JOURNAL (2014)
Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques
Noa Biran et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma
Mark Korthals et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma
Jacob Smeltzer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
Aristeidis Chaidos et al.
BLOOD (2013)
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders et al.
BLOOD (2013)
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Bruno Paiva et al.
BLOOD (2013)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
Saad Z. Usmani et al.
BLOOD (2013)
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial
Treen C. M. Morris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics
Jim F. Huggett et al.
CLINICAL CHEMISTRY (2013)
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
Andre Veillette et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
Alessandro Allegra et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Thorsten Derlin et al.
EUROPEAN RADIOLOGY (2013)
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J. Pessoa de Magalhaes et al.
HAEMATOLOGICA (2013)
Comparison of Droplet Digital PCR to Real-Time PCR for Quantitative Detection of Cytomegalovirus
R. T. Hayden et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
Prashant Kapoor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Minimal Residual Disease in Multiple Myeloma
Nikhil C. Munshi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma
Heinz Ludwig et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
G. Bianchi et al.
LEUKEMIA (2013)
Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
A. Bradwell et al.
LEUKEMIA (2013)
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients
H. Ludwig et al.
LEUKEMIA (2013)
Absolute quantification by droplet digital PCR versus analog real-time PCR
Christopher M. Hindson et al.
NATURE METHODS (2013)
Highly Precise Measurement of HIV DNA by Droplet Digital PCR
Matthew C. Strain et al.
PLOS ONE (2013)
Overview of clinical flow cytometry data analysis: recent advances and future challenges
Carlos E. Pedreira et al.
TRENDS IN BIOTECHNOLOGY (2013)
Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia
Wei Song et al.
ONCOLOGY LETTERS (2013)
Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma
Daisy Alapat et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation
Natalia Tovar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
Mark Korthals et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
IMWG consensus on maintenance therapy in multiple myeloma
Heinz Ludwig et al.
BLOOD (2012)
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
The peripheral CD138+population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients
David Chiron et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma
Noemi Puig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation
Peter Bannas et al.
EUROPEAN RADIOLOGY (2012)
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Teresa Paino et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
Jens Hillengass et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Yawara Kawano et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
Kristi Elkins et al.
MOLECULAR CANCER THERAPEUTICS (2012)
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients
N. Hosen et al.
LEUKEMIA (2012)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions
Lennard J. M. Dekker et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
Michele Cavo et al.
BLOOD (2011)
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay et al.
BLOOD (2011)
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni et al.
BLOOD (2011)
Roadmap for Harmonization of Clinical Laboratory Measurement Procedures
W. Greg Miller et al.
CLINICAL CHEMISTRY (2011)
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
Alessandro Allegra et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*
Brian M. Elliott et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
B. Paiva et al.
LEUKEMIA (2011)
Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis
S. Pfeifer et al.
LEUKEMIA (2011)
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Jean-Luc Harousseau et al.
BLOOD (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition
Carlos Fernandez de Larrea et al.
BLOOD (2009)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
Cheng E. Chee et al.
BLOOD (2009)
The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios
Seema Singhal et al.
BLOOD (2009)
Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients
Graham Peter Mead et al.
BLOOD (2009)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)
Serum Free Light Chain Ratio, Total κ/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Manuela M. Giarin et al.
CLINICAL CHEMISTRY (2009)
Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow
Mohd S. Iqbal et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
M. Dimopoulos et al.
LEUKEMIA (2009)
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
K. Noborio-Hatano et al.
ONCOGENE (2009)
Environmental-mediated drug resistance: a target for multiple myeloma therapy
Kenneth H. Shain et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Monitoring of minimal residual disease in multiple myeloma after allo-SCT:: flow cytometry vs PCR-based techniques
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2008)
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction:: the prognostic impact of achieving molecular response
Pilar Martinez-Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome
M. Tinguely et al.
CANCER SCIENCE (2008)
Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease
Colin A. Hutchison et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Prognostic value of immunophenotyping in multiple myeloma:: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma
Rosa Fonti et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Go with the flow for monitoring response in myeloma with minimal residual disease
Kylie D. Mason et al.
LEUKEMIA & LYMPHOMA (2008)
Haematopoietic stem cell release is regulated by circadian oscillations
Simon Mendez-Ferrer et al.
NATURE (2008)
Serum protein expression profiling in pediatric Hodgkin lymphoma: A report from the Children's Oncology Group
Lining Qi et al.
PEDIATRIC BLOOD & CANCER (2008)
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
David Gonzalez et al.
BLOOD (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee et al.
BLOOD (2007)
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
Marie-Christine Kyrtsonis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
T. Ise et al.
LEUKEMIA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
D Dingli et al.
BLOOD (2006)
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
GS Nowakowski et al.
BLOOD (2005)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
S Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
S Galimberti et al.
LEUKEMIA RESEARCH (2005)
Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment
M Perez-Andres et al.
LEUKEMIA (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia
JY Kwak et al.
EXPERIMENTAL HEMATOLOGY (2004)
Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens
N Sahara et al.
LEUKEMIA & LYMPHOMA (2004)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
AC Rawstron et al.
BLOOD (2002)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
H Avet-Loiseau et al.
BLOOD (2002)
Multiple myeloma: Evolving genetic events and host interactions
WM Kuehl et al.
NATURE REVIEWS CANCER (2002)
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
JF San Miguel et al.
BLOOD (2002)
Minimal residual disease monitoring in multiple myeloma
FE Davies et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2002)
Chromosome translocations in multiple myeloma
PL Bergsagel et al.
ONCOGENE (2001)
Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma
M Ladetto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
分享论文
